Microbio is pleased to have its collaboration with QUT, DSTG and DMTC Ltd highlighted in the 2021 DMTC Annual Report. See page 27 for the write up.

International medical device and pharmaceuticals consultant Dr Raffaella Giardino has joined the team at Microbio to drive commercialisation of the product suite in Europe.

Read more in the announcement: 211214_Microbio_welcomes_Raffaella_Giardino

Microbio is pleased to announce it has appointed a distributor in India for its range of COVID-19 tests.

The appointment of Indian firm, BioGTech, follows the approval of Microbio’s COVID-19 tests by the Indian Council of Medical Research (ICMR), and validation testing by Rajiv Gandhi Centre for Biotechnology (RGCB). The first deliveries to India are expected to be made in coming weeks.

Find out more in the media release: 211209_Microbio_prepares_for_first_deliveries_in_India

Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability.

More information can be found in the media release.

211019_Microbio_moves_toward_sovereign_manufacturing_of_diagnostic_tests

Microbio is pleased to announce its two COVID-19 tests have been approved for sale in Europe under the IVD Directive 98/79/EC.

More information can be found in the media release.

210916_Australian COVID-19 Tests approved for Europe Download

Microbio is pleased to share this profile published in The Yield, Spoke Corporate’s Investor and Industry News. Author Simon Shepherdson has perfectly captured Microbio’s exciting history and big plans for the future. https://spokecorporate.com/diagnostic-technology-set-to-change-the-world/

Microbio is pleased to share the Case Study published by Life Sciences Queensland detailing the recent Federal Government Accelerating Commercialisation Grant and commercialisation progress of its pathogen detection products. Read more at: https://www.lsq.com.au/case-study/microbio-new-diagnostic-tests-to-improve-the-identification-of-pathogens/

Microbio Pty Ltd, an Australian-owned biotech company has been awarded a Federal Government Accelerating Commercialisation Grant to commercialise Microbio’s InfectID-Blood Stream Infection (BSI) diagnostic assay. Read more in the full media release.

201123_Microbio_Release_CA_Grant_SuccessDownload

Microbio has developed a new type of COVID-19 test that has the potential to determine not only if someone has the virus but also if they are infectious.

Microbio today announced its ground-breaking InfectID-COVID-19-R test which has been independently validated to identify the presence of replication-competent SARS-CoV-2 virus in samples in 45 minutes (post RNA extraction). 

The full press kit and accompanying photographs can be found in this dropbox.

201021_Microbio_Release_Replicating_SARS-CoV-2_testDownload

Dr Flavia Huygens has been honoured with one of DMTC’s 2020 Excellence Awards. Dr Huygens received the Project Leadership Award: “In recognition of exemplary professional conduct in support of DMTC’s objectives.”

The awards evening was held during the DMTC Annual Conference, 11-12 March 2020 in Canberra. The conference highlights the projects building defence and national security capabilities through collaboration with industry.

Dr Huygens was also invited to present at the conference to share progress on a project to develop a highly sensitive and specific pathogen identification diagnostic test. This project is a collaboration between DMTC Ltd, Microbio and Queensland University of Technology.

Contact us

Complete this form to request more information on purchasing InfectID, including the COVID-19 Replicating assay, new product developments, or other enquiries.
  • This field is for validation purposes and should be left unchanged.